Global Blood Therapeutics, Inc. (NASDAQ:GBT)‘s stock had its “overweight” rating restated by investment analysts at Morgan Stanley in a report issued on Friday. They presently have a $56.00 target price on the stock, up from their prior target price of $51.00. Morgan Stanley’s target price suggests a potential upside of 73.11% from the company’s current price.

Several other equities research analysts have also issued reports on GBT. ValuEngine raised Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 10th. BidaskClub lowered Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, June 20th. Oppenheimer Holdings, Inc. initiated coverage on Global Blood Therapeutics in a research report on Friday, August 4th. They set an “outperform” rating and a $53.00 price target on the stock. J P Morgan Chase & Co reissued an “overweight” rating and set a $46.00 price target (up from $44.00) on shares of Global Blood Therapeutics in a research report on Tuesday, August 8th. Finally, Cowen and Company reissued an “outperform” rating and set a $83.00 price target on shares of Global Blood Therapeutics in a research report on Monday, August 14th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $55.73.

Global Blood Therapeutics (NASDAQ GBT) opened at 32.35 on Friday. Global Blood Therapeutics has a one year low of $13.35 and a one year high of $41.15. The stock has a 50 day moving average of $28.61 and a 200-day moving average of $29.62. The firm’s market capitalization is $1.41 billion.

Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings results on Monday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.61) by $0.06. During the same period last year, the business earned ($0.58) EPS. On average, equities analysts predict that Global Blood Therapeutics will post ($2.44) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Morgan Stanley Reiterates Overweight Rating for Global Blood Therapeutics, Inc. (GBT)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2017/10/08/morgan-stanley-reiterates-overweight-rating-for-global-blood-therapeutics-inc-gbt.html.

In other Global Blood Therapeutics news, insider Jung Choi sold 3,000 shares of the stock in a transaction on Friday, July 21st. The stock was sold at an average price of $30.00, for a total value of $90,000.00. Following the sale, the insider now directly owns 143,255 shares of the company’s stock, valued at $4,297,650. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Deval L. Patrick sold 27,053 shares of the stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $29.69, for a total value of $803,203.57. Following the completion of the sale, the director now directly owns 12,053 shares in the company, valued at $357,853.57. The disclosure for this sale can be found here. Insiders sold 36,053 shares of company stock worth $1,073,204 over the last ninety days. 5.30% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of GBT. Teachers Advisors LLC increased its position in Global Blood Therapeutics by 19.3% in the fourth quarter. Teachers Advisors LLC now owns 29,682 shares of the company’s stock worth $429,000 after buying an additional 4,812 shares during the period. Russell Investments Group Ltd. increased its position in Global Blood Therapeutics by 1,054.6% in the first quarter. Russell Investments Group Ltd. now owns 28,761 shares of the company’s stock worth $1,060,000 after buying an additional 26,270 shares during the period. Wells Fargo & Company MN increased its position in Global Blood Therapeutics by 25.3% in the first quarter. Wells Fargo & Company MN now owns 120,568 shares of the company’s stock worth $4,443,000 after buying an additional 24,363 shares during the period. Great West Life Assurance Co. Can acquired a new stake in Global Blood Therapeutics in the first quarter worth $129,000. Finally, Bank of New York Mellon Corp increased its position in Global Blood Therapeutics by 79.2% in the first quarter. Bank of New York Mellon Corp now owns 139,389 shares of the company’s stock worth $5,137,000 after buying an additional 61,593 shares during the period. 86.07% of the stock is currently owned by hedge funds and other institutional investors.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Analyst Recommendations for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Stock Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related stocks with our FREE daily email newsletter.